Legato Capital Management LLC Makes New Investment in United Therapeutics Corporation (NASDAQ:UTHR)

Legato Capital Management LLC acquired a new position in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 4,904 shares of the biotechnology company's stock, valued at approximately $1,512,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Dunhill Financial LLC increased its stake in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after acquiring an additional 50 shares in the last quarter. Sound Income Strategies LLC bought a new position in shares of United Therapeutics in the 1st quarter worth about $49,000. State of Wyoming bought a new position in shares of United Therapeutics in the 4th quarter worth about $62,000. Curat Global LLC bought a new position in shares of United Therapeutics in the 1st quarter worth about $63,000. Finally, Natixis bought a new position in shares of United Therapeutics in the 4th quarter worth about $85,000. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the firm's stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total value of $879,225.60. Following the transaction, the director owned 19,384 shares of the company's stock, valued at approximately $5,613,606.40. This trade represents a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total transaction of $3,079,560.00. Following the sale, the executive vice president owned 36,781 shares in the company, valued at approximately $10,297,208.76. The trade was a 23.02% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 81,681 shares of company stock worth $24,628,589. 10.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Wells Fargo & Company reissued an "equal weight" rating and set a $314.00 price objective (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. HC Wainwright reissued a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. UBS Group cut their price objective on shares of United Therapeutics from $410.00 to $385.00 and set a "buy" rating on the stock in a research report on Monday, June 30th. Finally, Morgan Stanley cut their price objective on shares of United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 10th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat, United Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $383.08.

United Therapeutics Stock Down 0.6%

Shares of NASDAQ UTHR traded down $1.91 during trading on Friday, reaching $304.50. 310,921 shares of the company traded hands, compared to its average volume of 372,488. The stock has a market capitalization of $13.74 billion, a PE ratio of 12.15, a P/E/G ratio of 6.64 and a beta of 0.53. The firm has a 50 day simple moving average of $300.01 and a 200-day simple moving average of $315.85. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. United Therapeutics had a net margin of 40.44% and a return on equity of 19.33%. The firm's revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the firm posted $6.17 earnings per share. As a group, research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.